Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Novartis ADR representing 1 Ord Shs NVS

Healthcare
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory... see more

Opinion & Analysis (NYSE:NVS)

EpiPen Rival Lands Major Partner

Streetwise Reports July 3, 2018

Biotech Round-Up: M&As, Financings and Immuno-Oncology

Streetwise Reports April 19, 2018

Analysts take note as small-cap biotech completes early enrollment for Phase 3 trial

The Life Sciences Report July 6, 2017

Big pharma sets its sights on NASH epidemic

The Life Sciences Report May 18, 2017

Stellar Biotechnologies (SBOT:NASDAQ) could rise with KLH vaccine trial success

The Life Sciences Report March 2, 2017

Partnerships propel Stellar Biotechnologies' vaccine technology

The Life Sciences Report June 22, 2016

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015

Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

George S. Mack September 3, 2015

Swiss Miss: Switzerland Skirts Recession, But ETFs Struggle

Benzinga.com  August 28, 2015

O'Leary's O'Shares Triples The Size Of Its ETF Stable

Benzinga.com  August 19, 2015

Opportunities in cancer immunotherapy throttle up: George Zavoico of JonesTrading

George S. Mack June 25, 2015

Capitalize on comeback stories in micro-cap biotech: Joe Pantginis of ROTH Capital Partners

George S. Mack June 17, 2015

Drug ETFs Attractive Buys On Pullback

Benzinga.com  October 22, 2014

ECB interest rate cuts and bond buying boosts ETFs

Benzinga.com  September 5, 2014

Two New WisdomTree International ETFs (IHDG, EUDG, BHP, NVS)

Benzinga.com  May 14, 2014

Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)

Benzinga.com  April 22, 2014

Investing in biotech stocks is not for amateurs (CLDX) (NPSP)

Marc Lichtenfeld January 17, 2014

Everyone gets the flu

Marc Lichtenfeld March 6, 2013

This tiny startup has scored "microchip medicine" breakthrough

Michael A. Robinson August 9, 2012

Cash in on the growing Chinese pharmaceutical market

Tony D'Altorio September 10, 2010